Bayer Tries to Rewrite Its Story with Biofuel and Pharma Pipeline, But Legal Shadow Lifts Only Briefly

Bayer stock gains 3% but no Monsanto spin-off; new BP alliance for Camelina biofuel and pharma acquisitions offer alternative growth catalysts.

Shares of Bayer climbed 3.07% to €35.58 on Thursday, a move that seemed to buck the broader narrative hanging over the stock. The advance, however, masked a deeper disappointment: Reuters reported that the company has no immediate plans to spin off its Monsanto unit, a structural solution many investors had pinned their hopes on. For now, the conglomerate is betting on operational fixes and a fresh strategic narrative to win over the market.

The decision to keep Monsanto inside the fold is rational — untangling it while litigation over glyphosate is still unresolved would be messy — but it leaves the equity case tied to incremental progress rather than a clean break. Over the past seven days, Bayer’s shares have lost 5.95%, and they remain 6.43% in the red since the start of the year. At 28.74% below the 52-week high of €49.93, the stock reflects a market that sees potential but demands concrete catalysts.

Yet amid the legal overhang, Bayer is quietly building a new growth story that stretches beyond the courtroom. The most intriguing strategic move in recent weeks is a long-term alliance with BP to commercialise the oilseed crop Camelina as a feedstock for biofuels under the brand newgold™. The tie-up, initially targeting North America, marries BP’s refining expertise with Bayer’s seed technology and farmer network. Camelina, grown as a cover crop on less intensively used land, opens a route into renewable diesel and sustainable aviation fuel. For Bayer, the deal transforms its seed business from a simple input seller into a player in an entirely new value chain — positioning the group as a link between agriculture and energy. It’s more than a sustainability project; it’s a strategic lever that could reshape how the market values the crop science division.

On the pharmaceutical side, Bayer is also trying to shift the conversation toward the future. The company announced it will fully acquire Perfuse Therapeutics, adding a glaucoma and diabetic retinopathy candidate, PER-001, to its ophthalmology pipeline. The deal is still subject to regulatory approvals. Additionally, data presented at ASCO for Nubeqa® in a head-to-head trial against enzalutamide in prostate cancer offered no breakthrough but provided a signal that the drug remains competitive. These moves, alongside earlier pipeline progress on Kerendia, finerenone, the FXIa inhibitor, and sevabertinib, are meant to steer the capital markets debate away from legacy costs and toward tomorrow’s product cycle.

But for the stock, these developments remain optionality — not reality. The relative strength index sits at 40.2, suggesting no euphoria, and the 38.4% annualised volatility underscores that investors still treat Bayer as an event-driven name rather than a steady compounder. The 50-day moving average of €38.44 stands about 7.5% above the current price, indicating the technical path is uphill.

Bayer’s operational numbers are better than the market’s mood would suggest. Full-year guidance was confirmed after the first quarter, and Crop Science improved its earnings. Yet without a visible reduction in legal risk — or a structural fix like a spin-off — the stock remains trapped between a turnaround story that is proceeding quietly and a legal shadow that refuses to lift. Thursday’s gain looks more like a technical bounce than a vote of confidence. Anyone betting on Bayer will need patience, and plenty of it.